Comparative Pharmacology
Head-to-head clinical analysis: BENLYSTA versus KEVZARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENLYSTA versus KEVZARA.
BENLYSTA vs KEVZARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Belimumab is a human IgG1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLyS, also known as BAFF), inhibiting its activity. BLyS is a cytokine that promotes B-cell survival and differentiation. By binding BLyS, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.
Interleukin-6 (IL-6) receptor antagonist; sarilumab binds specifically to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling through gp130 and STAT3.
10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).
200 mg subcutaneously once weekly.
None Documented
None Documented
Terminal half-life approximately 18.6 days (range 13–31 days) in patients with SLE, supporting monthly intravenous dosing.
Terminal elimination half-life ~21-22 days, supporting subcutaneous dosing every 2 weeks.
Not extensively characterized; expected to be degraded into small peptides and amino acids via general protein catabolism. Renal and fecal elimination are minor pathways.
Primarily eliminated via reticuloendothelial system catabolism. No significant renal or biliary excretion; <1% excreted unchanged in urine or feces.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody, IL-6 Receptor Antagonist